HUMANIZED IL-4 AND IL-4Ra ANIMALS
US-2017311580-A1 · Nov 2, 2017 · US
GM-CSF and IL-4 conjugates, compositions, and methods related thereto
US9657076B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9657076-B2 |
| Application number | US-201314436491-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 23, 2013 |
| Priority date | Oct 23, 2012 |
| Publication date | May 23, 2017 |
| Grant date | May 23, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
In certain embodiments, this disclosure relates to conjugates comprising GM-CSF and IL-4 and uses related thereto, e.g., enhancing the immune system. Typically the GM-CSF and IL-4 are connected by a linker. In certain embodiments, the disclosure relates to isolated nucleic acids encoding these polypeptide conjugates, vectors comprising nucleic acid encoding polypeptide conjugates, and protein expression systems comprising these vectors such as infectious viral particles and host cells comprising such a nucleic acids.
First claim
Opening claim text (preview).
What we claim: 1. A conjugate comprising a granulocyte macrophage colony stimulating factor (GM-CSF) polypeptide and an interleukin 4 (IL-4) polypeptide, wherein said conjugate comprises the amino acid sequence of SEQ ID NO: 8. 2. A pharmaceutical composition comprising the conjugate of claim 1 and a pharmaceutically acceptable excipient. 3. A vaccine comprising the conjugate of claim 1 and an antigen, optionally in combination with an adjuvant. 4. The vaccine of claim 3 , wherein the antigen is conjugated to the granulocyte macrophage colony stimulating factor polypeptide.
Assignees
Inventors
Classifications
Antivirals · CPC title
Antineoplastic agents · CPC title
Immunostimulants · CPC title
characterised by the immunostimulating additives, e.g. chemical adjuvants · CPC title
Blood; Artificial blood (perfluorocarbons A61K31/02; umbilical cord blood A61K35/51; haemoglobin A61K38/42) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9657076B2 cover?
- In certain embodiments, this disclosure relates to conjugates comprising GM-CSF and IL-4 and uses related thereto, e.g., enhancing the immune system. Typically the GM-CSF and IL-4 are connected by a linker. In certain embodiments, the disclosure relates to isolated nucleic acids encoding these polypeptide conjugates, vectors comprising nucleic acid encoding polypeptide conjugates, and protein e…
- Who is the assignee on this patent?
- Univ Emory, Children'S Healthcare Of Atlanta Inc, Children'S Healthcare Of Atlanta Inc
- What technology area does this patent fall under?
- Primary CPC classification C07K14/5406. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue May 23 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).